# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.
Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.22) by...
Tommy Tuberville is one of the most active traders as a member of Congress. Here's a look at what he recently bought and sold.
Cantor Fitzgerald analyst Kristen Kluska reiterates Humacyte (NASDAQ:HUMA) with a Overweight and maintains $7 price target.
Piper Sandler analyst Allison Bratzel maintains Humacyte (NASDAQ:HUMA) with a Neutral and maintains $4 price target.